CR20130312A - Respuesta inmune potenciada en la especie bovina - Google Patents

Respuesta inmune potenciada en la especie bovina

Info

Publication number
CR20130312A
CR20130312A CR20130312A CR20130312A CR20130312A CR 20130312 A CR20130312 A CR 20130312A CR 20130312 A CR20130312 A CR 20130312A CR 20130312 A CR20130312 A CR 20130312A CR 20130312 A CR20130312 A CR 20130312A
Authority
CR
Costa Rica
Prior art keywords
bovine species
immune response
potentiated
response potentiated
bovine
Prior art date
Application number
CR20130312A
Other languages
English (en)
Inventor
Albert Abraham
Daniel Keil
Jason Nickell
Christian Weiss
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CR20130312A publication Critical patent/CR20130312A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento de activación inmune que es efectivo para provocar una respuesta inmune no específica para antígenos en un miembro de la especie bovina. El procedimiento es particularmente efectivo para proteger un miembro de la especie bovina de enfermedades infecciosas y tratar animales afectados de una enfermedad infecciosa.
CR20130312A 2010-12-22 2013-06-21 Respuesta inmune potenciada en la especie bovina CR20130312A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426255P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
CR20130312A true CR20130312A (es) 2013-10-17

Family

ID=45444595

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130312A CR20130312A (es) 2010-12-22 2013-06-21 Respuesta inmune potenciada en la especie bovina

Country Status (34)

Country Link
US (3) US20130295167A1 (es)
EP (1) EP2654785B1 (es)
JP (2) JP6058550B2 (es)
KR (1) KR101940826B1 (es)
CN (2) CN108379576A (es)
AR (1) AR084510A1 (es)
AU (1) AU2011347464B2 (es)
BR (1) BR112013016231B1 (es)
CA (1) CA2822359C (es)
CL (1) CL2013001833A1 (es)
CO (1) CO6761354A2 (es)
CR (1) CR20130312A (es)
DK (1) DK2654785T3 (es)
DO (1) DOP2013000149A (es)
EC (1) ECSP13012709A (es)
ES (1) ES2722204T3 (es)
GT (1) GT201300168A (es)
HK (1) HK1259341A1 (es)
HR (1) HRP20190779T1 (es)
HU (1) HUE043473T4 (es)
IL (1) IL226733B (es)
LT (1) LT2654785T (es)
MX (1) MX345854B (es)
MY (1) MY167159A (es)
NZ (1) NZ612285A (es)
PL (1) PL2654785T3 (es)
PT (1) PT2654785T (es)
RU (1) RU2606855C2 (es)
SI (1) SI2654785T1 (es)
TR (1) TR201906323T4 (es)
TW (1) TWI587877B (es)
UA (1) UA118537C2 (es)
UY (1) UY33821A (es)
WO (1) WO2012084951A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2654785B1 (en) * 2010-12-22 2019-03-20 Bayer Intellectual Property GmbH Enhanced immune response in bovine species
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
MX2016010993A (es) 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
CN104825393B (zh) * 2015-01-16 2017-11-10 艾美科健(中国)生物医药有限公司 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
CA2993883A1 (en) 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in porcine species
JP2018521108A (ja) * 2015-07-31 2018-08-02 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh 水生種における免疫応答の増強
AU2017301528A1 (en) * 2016-07-26 2019-02-14 Bayer Animal Health Gmbh Increased fertility in bovine species
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
SG11202004773SA (en) * 2017-12-15 2020-06-29 Bayer Animal Health Gmbh Immunostimulatory compositions
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用
US11689594B2 (en) 2019-03-28 2023-06-27 Nec Corporation Information processing apparatus, server allocation apparatus, method, and computer readable medium
CN114480663A (zh) * 2021-11-15 2022-05-13 贵州省畜牧兽医研究所 用于检测猪源差异脲原体的引物对、试剂盒及检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6586409B1 (en) 1999-03-26 2003-07-01 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
RU2158587C1 (ru) * 1999-05-11 2000-11-10 Ставропольское научно-производственное объединение "Пульс" Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
MXPA03009632A (es) 2001-04-24 2004-06-30 Innogenetics Nv Proteinas de la envoltura de vhc glucosiladas en la estructura central.
JP2004537543A (ja) * 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
BRPI0408779A (pt) * 2003-03-26 2006-04-04 Wyeth Corp uso de composições, composição imunogênica e kit
AR044437A1 (es) * 2003-05-29 2005-09-14 Schering Plough Ltd Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino
AU2004280143A1 (en) * 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
JP2008094763A (ja) * 2006-10-12 2008-04-24 Takeshi Ogura 海洋ミネラル成分からなるインターフェロンγ産生増強剤
EP2249843A4 (en) * 2008-02-24 2013-05-08 Us Gov Health & Human Serv USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGENIC INFECTIONS
CA2719614C (en) * 2008-03-25 2018-05-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
US8815255B2 (en) * 2008-10-31 2014-08-26 Boehringer Ingelheim Vetmedica, Inc. Use of Mycoplasma bovis antigen
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
EP2654785B1 (en) 2010-12-22 2019-03-20 Bayer Intellectual Property GmbH Enhanced immune response in bovine species

Also Published As

Publication number Publication date
PL2654785T3 (pl) 2019-09-30
MX2013007064A (es) 2013-08-21
HUE043473T2 (hu) 2019-08-28
PT2654785T (pt) 2019-06-25
CN108379576A (zh) 2018-08-10
ECSP13012709A (es) 2013-08-30
NZ612285A (en) 2015-09-25
BR112013016231B1 (pt) 2021-03-23
MX345854B (es) 2017-02-17
UA118537C2 (uk) 2019-02-11
KR101940826B1 (ko) 2019-01-21
EP2654785B1 (en) 2019-03-20
DOP2013000149A (es) 2013-08-15
US10751361B2 (en) 2020-08-25
SI2654785T1 (sl) 2019-06-28
JP2017036290A (ja) 2017-02-16
JP6058550B2 (ja) 2017-01-11
HK1259341A1 (zh) 2019-11-29
HUE043473T4 (hu) 2019-12-30
CA2822359A1 (en) 2012-06-28
LT2654785T (lt) 2019-07-10
BR112013016231A2 (pt) 2016-09-27
CL2013001833A1 (es) 2014-06-20
TW201306877A (zh) 2013-02-16
EP2654785A1 (en) 2013-10-30
AR084510A1 (es) 2013-05-22
HRP20190779T1 (hr) 2019-06-28
CO6761354A2 (es) 2013-09-30
DK2654785T3 (da) 2019-06-24
ES2722204T3 (es) 2019-08-08
US20130295167A1 (en) 2013-11-07
WO2012084951A1 (en) 2012-06-28
KR20130132926A (ko) 2013-12-05
TWI587877B (zh) 2017-06-21
MY167159A (en) 2018-08-13
IL226733B (en) 2020-06-30
TR201906323T4 (tr) 2019-05-21
UY33821A (es) 2012-07-31
AU2011347464A1 (en) 2013-07-11
AU2011347464B2 (en) 2016-08-25
CA2822359C (en) 2021-06-01
US20140010865A1 (en) 2014-01-09
RU2013133730A (ru) 2015-01-27
RU2606855C2 (ru) 2017-01-10
GT201300168A (es) 2015-02-23
US20190201434A1 (en) 2019-07-04
AU2011347464A2 (en) 2013-08-22
CN103501810A (zh) 2014-01-08
JP2014500292A (ja) 2014-01-09

Similar Documents

Publication Publication Date Title
ECSP13012709A (es) Respuesta inmune potenciada en la especie bovina
CR20110595A (es) Respuesta inmunitaria reforzada en especies aviares
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
GT201200318A (es) Anticuerpos hacia gdf8 humano
UY34995A (es) Formulaciones de anticuerpo y proteína
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
CR20120404A (es) Proteinas de enlace cd127
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
ECSP14020644A (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
BR112014020019A8 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
CO2018002207A2 (es) Composiciones contra alergia a los gatos
IN2014CN04071A (es)
CO2019001112A2 (es) Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas
CR20140121A (es) Formulaciones para los campos de arrozales
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112017007860A2 (pt) método para tratar uma doença de gordura no fígado
MX2017000869A (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
NI201300058A (es) Respuesta inmune potenciada en la especie bovina
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
BR112015028986A2 (pt) métodos para produzir partículas compreendendo proteínas terapêuticas
NZ629420A (en) Sheep nematode vaccine
AR083637A1 (es) Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas a enfermedades neurodegenerativas